The road to approved vaccines for respiratory syncytial virus.

ABSTRACT: After decades of work, several interventions to prevent severe respiratory syncytial virus (RSV) disease in high-risk infant and older adult populations have finally been approved. There were many setbacks along the road to victory. In this review, I will discuss the impact of RSV on human health and how structure-based vaccine design set the stage for numerous RSV countermeasures to advance through late phase clinical evaluation. While there are still many RSV countermeasures in preclinical and early-stage clinical trials, this review will focus on products yielding long-awaited efficacy results. Finally, I will discuss some challenges and next steps needed to declare a global victory against RSV.

SUBMITTER: Ruckwardt TJ 

PROVIDER: S-EPMC10519952 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature